Braveheart Posts $26.5M Q3 Loss, $503.5M Cash Funds Runway Into 2029
BRVE sits 17% above its 52-week low of $16.7.
Summary
Braveheart reported a $26.5 million net loss, or $0.51 per share, for Q3 2026, with R&D at $17.5 million and G&A at $12.6 million. Cash, cash equivalents and investments stood at $503.5 million as of September 30, which the company says funds operations into 2029 — a long runway for a clinical-stage biotech. The update follows the November 6 AHA presentation of 52-week open-label extension data for BHB-1893 in oHCM, where pVO2 improved 2.7 mL/kg/min and KCCQ-CSS 17.3 points, and 57% of patients stayed on the 40 mg twice-daily starting dose at Week 52. Development plans are laid out: LIONHEART-HCM Phase 3 is enrolling with an interim LVOT-gradient analysis expected in the second half of 2027, while TRUEHEART-HCM Phase 2b and NOBLEHEART-HCM Phase 3 are slated to start in the first half of 2027. Partner Hengrui has finished enrollment in its China Phase 3 (Study 301), with topline results expected in the first half of 2027.
At the time of this announcement, BRVE was trading at $19.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $16.70 to $32.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.